Combinations of cancer drugs can be quickly and cheaply tested on tumour cells using a novel device developed by EMBL scientists. The research, reported in Nature Communications on June 22, marks the latest advancement in the field of personalised medicine.
Using a microfluidic device that fits in the palm of your hand, scientists screened over 1100 treatment conditions (56 drug combinations x 20 replicates) on patient tumour cells. In the future, such tests could be used to inform clinicians on safe and effective combinations of cancer treatments. This research, incorporating fundamental science alongside clinical expertise at Aachen University Hospital, was led by EMBL group leader Christoph Merten and Julio Saez-Rodriguez, former group leader at EMBL-EBI and now Professor at Heidelberg University.
Small biopsies, many drugs
Directly testing multiple cancer drugs on biopsies – parts of the tumour which have been taken from a patient – is a powerful way to discover which drugs work best, and for whom. This is because depending on the specific tumour characteristics, cancer therapies can be more effective in some people than others. However, large-scale patient specific drug screenings have so far been limited by the small biopsy size that can typically be obtained from patients. That is why in the current paper, the team developed a miniaturised device which can test more drugs on a limited number of cells.
The research team initially tested 56 drug combinations on two different human cancer cell types grown in the lab. Drug combinations which killed both types of cancer cells were thought to be potentially toxic and thus unsafe for further testing. However, some drug combinations which targeted and killed only one type of cancer cell were found to be more effective than standard clinical therapies which only use one drug. These results were highly reproducible and could be validated in mouse models of human cancer.
Subsequently, cells from four cancer patient biopsies were applied to the microfluidic device and different drug combinations were tested. “We found that each individual cancer responded best to a different combination of drugs, highlighting the urgent need for patient-specific therapies,” says Federica Eduati, joint first author on the paper alongside Ramesh Utharala who designed and developed the microfluidic device.
“Before we transfer this technology into the clinics, we need to repeat these experiments in larger-scale mouse studies to understand which types of cancer this technology works best in,” says Christoph Merten. “Still, this is an exciting ‘proof of principle’ collaboration between scientists and clinicians, and we have shown that these tests can be run quickly and for less than $150 USD per patient.”
The Latest on: Personalized medicine
via Google News
The Latest on: Personalized medicine
- Strategic Evaluation of Precision Medicine: Country Analysis for Emerging Opportunities on September 18, 2018 at 12:53 pm
which have approximately doubled during the past five years and are expected to increase by 30% during the next three years.Approximately 69% of drug development during the ensuing five years is predi... […]
- Personalized Medicine in Prostate Cancer: Now More Precise on September 18, 2018 at 12:30 pm
Over the past decade, we have witnessed an explosion of molecular testing in the urology world that will help us better diagnose and manage prostate cancer across the spectrum of the disease. All of u... […]
- Software could lead to personalized leukemia treatments on September 18, 2018 at 11:06 am
Early findings from a new study could help in the development of immune-based treatments personalized to people with acute myeloid ... an assistant professor in the School of Medicine division of hema... […]
- Advanced Diagnostics for Personalized Medicine on September 14, 2018 at 6:21 am
For most of the 20th century all women with breast cancer received similar treatment. Therapy has since become more individualized: breast cancers are now divided into subtypes and treated accordingly ... […]
- Expert Explores Emerging Role of Personalized Medicine in HCC Treatment on September 14, 2018 at 6:14 am
Updates to the European Association for the Study of the Liver (EASL) clinical guidelines introduce more opportunities for individual patient management of hepatocellular carcinoma (HCC), explained Fa... […]
- Cancer Biomarkers Market is Forecast to Reach US$27.63 Billion by 2025; Rising Focus on Personalized Medicine to Accelerate Growth - TMR on September 14, 2018 at 4:05 am
The global cancer biomarkers market has been growing at a fast pace, owing to the research and development activities. The developing economies hold promising growth opportunities for the market playe... […]
- If you want personalized medicine, we’ll need to know what time it is in your liver on September 12, 2018 at 3:00 pm
Stop! It's body clock time. Back in 1960, researchers discovered that a specific toxin, given to a mouse at one time of the day, would kill it. Administer the same poison at a different time, and the ... […]
- InformedDNA Selected to Provide Genetic Counseling to Participants in Coriell Institute’s Personalized Medicine Collaborative Research Study on September 12, 2018 at 7:48 am
ST. PETERSBURG, Fla.--(BUSINESS WIRE)--InformedDNA ®, the nation's largest independent provider of expert genetics services, has been selected by the Coriell Institute for Medical Research to provide ... […]
- Following the tumor DNA trail to crack the secrets of personalized medicine on September 10, 2018 at 10:53 am
Paris, France, 10 September 2018 - Individualised therapies that target the specific genetic features of tumours have the potential to transform cancer diagnosis, treatment and care. However, several ... […]
via Bing News